[VIRTUAL] AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial

[VIRTUAL] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study

[VIRTUAL] GEMSTONE-302: A phase III study of platinum:based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

[VIRTUAL] A phase II study investigating neoadjuvant atezolizumab in cisplatin:ineligible patients with muscle:invasive bladder cancer: Final analysis

[VIRTUAL] Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple:negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation

[VIRTUAL] Efficacy and safety of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose: A Subgroup Analysis of A Randomized, Double:Blind, Placebo-Controlled, Phase 3 Trial

[VIRTUAL] Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia

[VIRTUAL] Randomized, multicenter trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small cell lung cancer: NCT01631357

[VIRTUAL] Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

[VIRTUAL] Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza) - resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199

[VIRTUAL] Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

[VIRTUAL] Sintilimab plus bevacizumab biosimilar vs sorafenib as first:line treatment for advanced hepatocellular carcinoma (ORIENT-32)2

[VIRTUAL] Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study

[VIRTUAL] Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea

[VIRTUAL] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)